References

ateroskleroz

Атеросклероз

Ateroscleroz

2078-256X2949-3633

НИИТПМ-филиал ИЦиГ СО РАН

10.15372/ATER20200207

ateroskleroz-378

Research Article

ОБЗОРЫ

REVIEWS

COVID-19 и сердечно-сосудистые заболевания

COVID-19 and cardiovascular diseases

Полонская

Я. В.

Polonskaya

Ya. V.

Полонская Яна Владимировна – доктор биологических наук, старший научный сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

630089, Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

yana-polonskaya@yandex.ru

Каштанова

Е. В.

Kashtanova

E. V.

Каштанова Елена Владимировна – доктор биологических наук, заведующий лабораторией клинических биохимических и гормональных исследований терапевтических заболеваний

630089, Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

elekastanova@yandex.ru

Стахнёва

Е. М.

Stakhneva

E. M.

Стахнёва Екатерина Михайловна – кандидат биологических наук, старший научный сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

630089, Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

stahneva@yandex.ru

Садовский

Е. В.

Sadowski

E. V.

Садовский Евгений Викторович – младший научный сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

630089, Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

sadovskij.e.v.83@mail.ru

Рагино

Ю. И.

Ragino

Yu. I.

Рагино Юлия Игоревна – доктор медицинских наук, чл.-корр. РАН, руководитель НИИТПМ – филиал ИЦиГ СО РАН

630089, Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

ragino@mail.ru

НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАНResearch Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS

2020

24072020

1627379

2020

Полонская Я.В., Каштанова Е.В., Стахнёва Е.М., Садовский Е.В., Рагино Ю.И.

Polonskaya Y.V., Kashtanova E.V., Stakhneva E.M., Sadowski E.V., Ragino Y.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://ateroskleroz.elpub.ru/jour/article/view/378

На начало июня 2020 г. в мире выявлено более 7 млн человек с COVID-19 – новой коронавирусной инфекцией, распространившейся по всему миру, более 400 тысяч человек умерло. В России количество заболевших превысило 470 000 человек, погибло более 5900 [https:// covid19-2020.info/]. Все больше исследователей сообщают о высокой вероятности развития инфекции и неблагоприятном течении болезни у лиц с сердечно-сосудистыми заболеваниями, что обусловливает необходимость изучения влияния SARS-CoV-2 на сердечно-сосудистую систему. Дан анализ публикаций за 2020 г. из баз данных PubMed, Google Scholar и E-library, посвященных этому вопросу.

At the beginning of June 2020, more than 7 million people were identified worldwide with COVID-19, a new coronavirus infection that has spread around the world, more than 400 thousand people have died. In Russia, the number of cases exceeded 470 000 people, and more than 5900 died [https://covid19-2020.info/]. More and more researchers report a greater likelihood of infection and adverse disease course in people with cardiovascular diseases, which makes it necessary to study the effect of SARS-CoV-2 on the cardiovascular system. This article provides an analysis of the publications for the year 2020 from the databases of PubMed, Google Scholar, and E-library on this issue.

сердечно-сосудистые заболеванияCOVID-19коронавирус

cardiovascular diseasesCOVID 19coronavirus

References1

Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.

Carlos W.G., Dela Cruz C.S., Cao B., et al. Novel Wuhan (2019-nCoV) Coronavirus. Am. J. Respir. Crit. Care. Med. 2020; 201: P7-P8.

WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019 – nCoV) [online]. (2020). Available: https:// www.who.int/news-room/detail/30-01-2020-statementon-the-second-meeting-of-theinternational-health-regulations-(2005)-emergency-committee-regarding-theoutbreak-of-novelcoronavirus-(2019-ncov)а

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/ naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it 2 5. https://covid19-2020.info/

Gaythorpe K., Imai N., Cuomo-Dannenburg G., et al. With support from other volunteers from the MRC Centre. et al. Symptom progression of COVID-19. Imperial College London (11-03-2020). doi: https://doi.org/10.25561/77344

Lai C.C., Liu Y.H., Wang C.Y., et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J. Microbiol. Immunol. Infect. 2020. doi: 10.1016/j.jmii.2020.02.012

Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41: 145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003

Arentz M.Y., Klaff L., Lokhandwala S., et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020; doi: 10.1001/jama.2020.4326

Yang X., Yu Y., Xu J., Shu H., et al. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; doi: 10.1016/S2213-2600(20)30079-5

Liu K., Fang Y.Y., Deng Y., et al.. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl). 2020; 133: 1025–1031.

Wang D., Hu B., Hu C., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020, doi: 10.1001/jama.2020.1585.

Zhang J.J., Dong X., Cao Y.Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. doi: 10.1111/all.14238.

Mo P., Xing Y., Xiao Y., et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin. Infect. Dis. 2020. doi: 10.1093/cid/ciaa270

Guo T., Fan Y., Chen M., et al.Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1017

Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. doi: 10.1016/S0140-6736(20)30566-3

Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091.

Wang L., He W., Yu X., et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J. Infection. 2020. https://doi.org/10.1016/j.jinf.2020.03.019

Shi S., Qin M., Shen B., et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020, doi: 10.1001/jamacardio.2020.0950

Lian J., Jin X., Hao S., et al. Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID-19) out of Wuhan. Clin. Infect. Dis. 2020; pii: ciaa242. https://doi.org/10.1093/cid/ciaa242

Guan W.J.N.Z., Hu Y., Liang W.H., et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2002032

Guan W., Ph D., Liang W., et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis. Eur. Respir. J. 2020. https://doi.org/10.1183/13993003.00547-2020

Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2006923

Mehra M.R., Desai S.S., Kuy S., Henry T.D. and Patel A.N. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2007621

Reynolds H.R., Adhikari S., Pulgarin C., et al. ReninAngiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N. Engl. J. Med. 2020. doi: 10.1056/ NEJMoa2008975

Du R.-H., Liang L.-R., Yang C.-Q. et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur. Res. 2020; 55 (4). doi: 10.1183/13993003.00524-2020 11

Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020 https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf

Yingzhen Du, Lei Tu, Pingjun Zhu, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study AJRCCM Articles in Press. Published April 03, 2020 as 10.1164/rccm.202003-0543OC Copyright © 2020 by the American. www.atsjournals.org/doi/pdf/10.1164/rccm.202003-0543OC

Chen T. Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Br Med J. 2020;1091(March): m1091.https://doi.org/oi.org/doi:10.1136/bmj.m1091 Li B

Yang J., Zhao F.L. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020; (0123456789). https://doi.org/10.1007/s00392-020-01626-9

Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and metaanalysis. Int. J. Infect. Dis. 2020 Mar 12. pii: S1201- 9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017

Inciardi R.M.A.M., Lupi L., Cani D.S., et al. Characteristics and outcomes of patients hospitalized for COVID19 and cardiac disease in Northern Italy. Eur. Heart J. 2020, doi: 10.1093/eurheartj/ehaa388

Wei J.F., Huang F.Y., Xiong T.Y. et al. Acute myocardial injury is common in patients with covid-19 and impairs their prognosis. Heart. 2020. doi: 10.1136/heartjnl-2020-317007

Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020; 5: 1–3. doi: 10.1007/s00059-020-04909-z. 4

Arentz M., Yim E., Klaff L. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020; 323 (16): 1612– 1614. doi: 10.1001/jama.2020.4326. 6

Hui H., Zhang Y., Yang X. et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. 2020: 2020.02.24.20027052. 8

Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020; 8: 420–422.

Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418.

Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T., Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020, doi: 10.1161/CIRCULATIONAHA.120.047349

Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020, doi: 10.1001/jamainternmed.2020.0994

Liu J., Li S., Liu J., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv. 2020 2020.02.16.20023671

Guan W. J., Ni Z.Y., Hu Y., et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. doi: 10.1101/2020.02.06.20020974

Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease (COVID-19): Evidence from a meta-analysis. Prog. Cardiovasc. Dis. 2020. [Epub ahead of print]. doi: 101016/j.pcad.2020.03.001

Zhou F., Yu T., Du R. et al. Clinical course and risk factorsfor mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.

Zheng Y.Y., Ma Y., Zhang J., et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020, doi: 101038/s41569-020-0360-5

Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. March 5, 2020; doi: 101016/j.cell.2020.02.052. [epub ahead of print]

Tikellis C., Thomas M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int. J. Pept. 2012; 2012: 256294-256294. doi: 101155/2012/256294

Zhang H., Penninger J.M., Li Y., et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. March 3, 2020; doi: 101007/s00134-020-05985-9

Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Diz D.I. Gallagher P.E. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111: 2605–2610.

Zisman L.S., Keller R.S., Weaver B., Lin Q., Speth R., Bristow M.R. Canver C.C. Increased angiotensin- (1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensinconverting enzyme Homologue ACE2. Circulation. 2003; 108: 1707–1712.

Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B. Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43: 970–976.

Epelman S., Tang W.H., Chen S.Y., Van Lente F., Francis G.S., Sen S. Detection of soluble angiotensinconverting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin-aldosterone system. J. Am. Coll. Cardiol. 2008; 52: 750–754.

Ohtsuki M., Morimoto S.I., Izawa H., Ismail T.F., Ishibashi-Ueda H., Kato Y., Horii T., Isomura T., Suma H., Nomura M., Hishida H., Kurahashi H. and Ozaki Y. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int. J. Cardiol. 2010; 145: 333–334.

Sama I.E.R.A., Santema B.T., van Goor H., ter Maaten J.M., Cleland J.G.F., Rienstra M., Friedrich A.W., Samani N.J., Ng L.L., Dickstein K., Lang C.C., Filippatos G., Anker S.D., Ponikowski P., Metra M., van Veldhuisen D.J., Voors A.A. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur. Heart J. 2020, doi: 10.1093/eurheartj/ehaa373

Guo J., Huang Z., Lin L. Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Am. Heart Assoc. 2020; 9: e016219.

Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., Crackower M.A., Fukamizu A., Hui C.C., Hein L., Uhlig S., Slutsky A.S., Jiang C. Penninger J.M. Angiotensinconverting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436: 112–116.

Raiden S., Nahmod K., Nahmod V., Semeniuk G., Pereira Y., Alvarez C., Giordano M. Geffner J.R. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J. Pharmacol. Exp. Ther. 2002; 303: 45–51.

Hui D.S.C., Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am. 2019; 33 (4): 869–889. doi: 10.1016/j.idc.2019.07.001

Azhar E.I., Hui D.S.C., Memish Z.A., et al. The Middle East respiratory syndrome (MERS). Infect Dis. Clin. North Am. 2019; 33 (4): 891–905. doi: 101016/j.idc.2019.08.001

Li G., Fan Y., Lai Y., et al. Coronavirus infections and immune responses. Med. Virol. 2020; 92 (4): 424– 32. doi: 101002/jmv.25685

Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017; 39 (5): 529–539. doi:101007/s00281-017-0629-x

Tang N., Li D., Wang X., et al. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020. doi: 101H11/jth14768

Klok F.A., Kuip M., van der Meer N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi: 10.1016/j.thromres.2020.04.013

Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418.

The authors declare that there are no conflicts of interest present.